FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1816641574> ?p ?o ?g. }

• W1816641574 endingPage "75" @default.
• W1816641574 startingPage "66" @default.
• W1816641574 abstract "Summary This study evaluated the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Three cohorts of six subjects received two different doses of plerixafor separated by at least 2 weeks to allow for adequate pharmacodynamic wash‐out. The following dosing cohorts were evaluated: 0·24 and 0·32 mg/kg (Cohort 1); 0·32 and 0·40 mg/kg (Cohort 2); and 0·40 and 0·48 mg/kg (Cohort 3). Circulating CD34+ cells were measured 0, 2, 4, 6, 8, 10, 12, 14, 18 and 24 h after each dose. Blood colony‐forming units were measured at baseline and 6 h after each dose. Common adverse events were diarrhoea, injection site erythema, perioral numbness, sinus tachycardia, headache, nausea, abdominal distention and injection site pain. No dose limiting toxicities occurred. When higher doses of plerixafor were administered, there was a trend towards higher peak CD34+ counts and CD34+ area under the curves, although these differences did not achieve statistical significance, perhaps due to intra‐subject variability. Together, these data show that the higher doses of plerixafor evaluated in this study are reasonably safe and suggest that a larger study should be performed to definitively answer whether increased numbers of CD34+ cell are mobilized with higher doses of plerixafor." @default.
• W1816641574 created "2016-06-24" @default.
• W1816641574 creator A5001134935 @default.
• W1816641574 creator A5004913924 @default.
• W1816641574 creator A5012614494 @default.
• W1816641574 creator A5043805146 @default.
• W1816641574 creator A5059096564 @default.
• W1816641574 creator A5063279617 @default.
• W1816641574 creator A5068073723 @default.
• W1816641574 creator A5069187265 @default.
• W1816641574 creator A5076074380 @default.
• W1816641574 creator A5077082272 @default.
• W1816641574 creator A5078176723 @default.
• W1816641574 creator A5080463871 @default.
• W1816641574 creator A5086881244 @default.
• W1816641574 creator A5087049535 @default.
• W1816641574 date "2011-02-24" @default.
• W1816641574 modified "2023-10-18" @default.
• W1816641574 title "A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers" @default.
• W1816641574 cites W1532162953 @default.
• W1816641574 cites W1978321902 @default.
• W1816641574 cites W1985902169 @default.
• W1816641574 cites W1987266525 @default.
• W1816641574 cites W1994163509 @default.
• W1816641574 cites W2030846042 @default.
• W1816641574 cites W2031221162 @default.
• W1816641574 cites W2034573495 @default.
• W1816641574 cites W2047025080 @default.
• W1816641574 cites W2056156788 @default.
• W1816641574 cites W2059933109 @default.
• W1816641574 cites W2076267122 @default.
• W1816641574 cites W2078918374 @default.
• W1816641574 cites W2086578993 @default.
• W1816641574 cites W2120892454 @default.
• W1816641574 cites W2124090816 @default.
• W1816641574 cites W2124514001 @default.
• W1816641574 cites W2124527582 @default.
• W1816641574 cites W2169584423 @default.
• W1816641574 doi "https://doi.org/10.1111/j.1365-2141.2010.08547.x" @default.
• W1816641574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3879799" @default.
• W1816641574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21352197" @default.
• W1816641574 hasPublicationYear "2011" @default.
• W1816641574 type Work @default.
• W1816641574 sameAs 1816641574 @default.
• W1816641574 citedByCount "27" @default.
• W1816641574 countsByYear W18166415742012 @default.
• W1816641574 countsByYear W18166415742013 @default.
• W1816641574 countsByYear W18166415742014 @default.
• W1816641574 countsByYear W18166415742015 @default.
• W1816641574 countsByYear W18166415742016 @default.
• W1816641574 countsByYear W18166415742017 @default.
• W1816641574 countsByYear W18166415742018 @default.
• W1816641574 countsByYear W18166415742019 @default.
• W1816641574 countsByYear W18166415742020 @default.
• W1816641574 countsByYear W18166415742021 @default.
• W1816641574 countsByYear W18166415742022 @default.
• W1816641574 crossrefType "journal-article" @default.
• W1816641574 hasAuthorship W1816641574A5001134935 @default.
• W1816641574 hasAuthorship W1816641574A5004913924 @default.
• W1816641574 hasAuthorship W1816641574A5012614494 @default.
• W1816641574 hasAuthorship W1816641574A5043805146 @default.
• W1816641574 hasAuthorship W1816641574A5059096564 @default.
• W1816641574 hasAuthorship W1816641574A5063279617 @default.
• W1816641574 hasAuthorship W1816641574A5068073723 @default.
• W1816641574 hasAuthorship W1816641574A5069187265 @default.
• W1816641574 hasAuthorship W1816641574A5076074380 @default.
• W1816641574 hasAuthorship W1816641574A5077082272 @default.
• W1816641574 hasAuthorship W1816641574A5078176723 @default.
• W1816641574 hasAuthorship W1816641574A5080463871 @default.
• W1816641574 hasAuthorship W1816641574A5086881244 @default.
• W1816641574 hasAuthorship W1816641574A5087049535 @default.
• W1816641574 hasBestOaLocation W18166415741 @default.
• W1816641574 hasConcept C111113717 @default.
• W1816641574 hasConcept C112705442 @default.
• W1816641574 hasConcept C126322002 @default.
• W1816641574 hasConcept C126894567 @default.
• W1816641574 hasConcept C129470790 @default.
• W1816641574 hasConcept C13373296 @default.
• W1816641574 hasConcept C170493617 @default.
• W1816641574 hasConcept C197934379 @default.
• W1816641574 hasConcept C2777288759 @default.
• W1816641574 hasConcept C2778828106 @default.
• W1816641574 hasConcept C2780580376 @default.
• W1816641574 hasConcept C42219234 @default.
• W1816641574 hasConcept C71924100 @default.
• W1816641574 hasConcept C72563966 @default.
• W1816641574 hasConcept C98274493 @default.
• W1816641574 hasConceptScore W1816641574C111113717 @default.
• W1816641574 hasConceptScore W1816641574C112705442 @default.
• W1816641574 hasConceptScore W1816641574C126322002 @default.
• W1816641574 hasConceptScore W1816641574C126894567 @default.
• W1816641574 hasConceptScore W1816641574C129470790 @default.
• W1816641574 hasConceptScore W1816641574C13373296 @default.
• W1816641574 hasConceptScore W1816641574C170493617 @default.
• W1816641574 hasConceptScore W1816641574C197934379 @default.
• W1816641574 hasConceptScore W1816641574C2777288759 @default.
• W1816641574 hasConceptScore W1816641574C2778828106 @default.
• W1816641574 hasConceptScore W1816641574C2780580376 @default.

• next